Shots:

• In Apr 2020- Mallinckrodt’s Stratatech initiated StrataGraft’s BLA submission process which is a regenerative skin tissue therapy to develop therapies for deep partial-thickness thermal burns in adults
• The BLA submission is based on P-III STRATA2016 clinical trial published in Journal of Burn Care & Research and is supported by STRATA2011 clinical trial (Published in Burns) further for presentation at the American Burn Association 52nd Annual Meeting
• StrataGraft regenerative skin tissue therapy is targeted for the reduction of autograft in patients with severe thermal burns and is cryopreserved for delivering viable cells upon application. The therapy has also received the US FDA’s ODD and was a novel product designated as Regenerative Medicine Advanced Therapy (RMAT) under the provisions of the 21st Century Cures Act

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance